Peptides for Metabolic

The metabolic category is the largest on PeptideTrace, covering 46 compounds across endocrine regulation, gastrointestinal function, bone metabolism, calcium homeostasis, and oncology-adjacent diagnostics. Twenty-seven of these hold regulatory approval in at least one tracked jurisdiction — more than any other research area.

The breadth here is important to understand. This category spans somatostatin analogues like octreotide and lanreotide (used in neuroendocrine tumour management), GLP-1 receptor agonists like dulaglutide and exenatide (metabolic and glycaemic control), bone-active agents like teriparatide and abaloparatide, and gut-targeted peptides like linaclotide and teduglutide. These are established medicines with decades of clinical data behind them.

The 15 research compounds include mitochondrial peptides (MOTS-c, humanin, SS-31) and Russian bioregulatory peptides (pancragen, vesugen, cardiogen) that are studied in preclinical settings but lack the controlled trial data of their approved counterparts. Four compounds are in active clinical development, including survodutide for MASH — a metabolic liver condition with no currently approved peptide treatment.